Silence Therapeutics plc Net Income | SLN

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.^[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Silence Therapeutics plc

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-43.3 M	-40.5 M	-39.4 M	-22.1 M	-19.6 M	-18.4 M	-1.62 M	-8.44 M	-6.64 M	-11.1 M	-9 M	-26.3 M	-5.74 M

All numbers in GBP currency

Indicator range from annual reports

Maximum	Minimum	Average
-1.62 M	-43.3 M	-19.4 M

Quarterly Net Income Silence Therapeutics plc

2026-Q1	2025-Q3	2025-Q2	2025-Q1	2023-Q4	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-43.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in GBP currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-43.3 M	-43.3 M	-43.3 M

References

Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer	Net Income	Price	% 24h	Market Cap	Country
Windtree Therapeutics WINT	-1.79 M	-	-	$ 26.8 M	USA
Trean Insurance Group TIG	-66 M	-	-	$ 316 M	USA
SQZ Biotechnologies Company SQZ	-79.5 M	-	57.95 %	$ 12.8 M	USA
Brickell Biotech BBI	-5.69 M	-	-5.38 %	$ 6.06 M	USA
Applied Therapeutics APLT	-106 M	-	-	$ 8.42 M	USA
ESSA Pharma EPIX	-28.5 M	-	-	$ 8.86 M	Canada
Generation Bio Co. GBIO	-132 M	-	-	$ 344 M	USA
Clearside Biomedical CLSD	-34.4 M	-	-	$ 25.3 M	USA
MEI Pharma MEIP	-71.2 M	-	10.43 %	$ 20.5 M	USA
Palatin Technologies PTN	-8.38 M	-	-	$ 13 M	USA
Институт стволовых клеток человека ISKJ	72.9 M	-	-	-	Russia
Lyra Therapeutics LYRA	-28.9 M	-	-	$ 24.9 M	USA
Завод ДИОД DIOD	37.2 M	-	-	-	Russia
Фармсинтез LIFE	-525 M	-	-	-	Russia
Ionis Pharmaceuticals IONS	-381 M	$ 43.5	0.62 %	$ 6.96 B	USA
Agios Pharmaceuticals AGIO	-413 M	$ 31.25	0.88 %	$ 1.81 B	USA
Foghorn Therapeutics FHTX	-74.3 M	$ 2.0	0.74 %	$ 126 M	USA
Inhibikase Therapeutics IKT	-48.3 M	$ 2.0	0.5 %	$ 197 M	USA
Kamada Ltd. KMDA	20.2 M	$ 8.0	1.34 %	$ 461 M	Israel
Intellia Therapeutics NTLA	-413 M	$ 12.75	4.0 %	$ 1.38 B	USA
Ultragenyx Pharmaceutical RARE	-575 M	$ 14.5	3.19 %	$ 1.43 B	USA
Viridian Therapeutics VRDN	-343 M	$ 19.0	2.16 %	$ 1.93 B	USA
AbbVie ABBV	1.82 B	$ 265.76	1.12 %	$ 470 B	USA
AbCellera Biologics ABCL	-146 M	$ 13.78	0.29 %	$ 4.12 B	Canada
Abeona Therapeutics ABEO	-71.2 M	$ 5.11	1.59 %	$ 271 M	USA
Arbutus Biopharma Corporation ABUS	-33.5 M	$ 4.67	4.94 %	$ 895 M	Canada
ACADIA Pharmaceuticals ACAD	391 M	$ 20.11	0.8 %	$ 3.39 B	USA
Achieve Life Sciences ACHV	-54.6 M	$ 7.01	0.13 %	$ 306 M	USA
AC Immune SA ACIU	-70.4 M	$ 2.71	0.55 %	$ 273 M	Schweiz
Aclaris Therapeutics ACRS	-64.9 M	$ 4.27	0.79 %	$ 523 M	USA
Adagene ADAG	-17.6 M	$ 2.8	0.28 %	$ 165 M	China
ADC Therapeutics SA ADCT	-143 M	$ 1.23	8.85 %	$ 156 M	Schweiz
Adial Pharmaceuticals ADIL	-7.98 M	$ 4.35	5.58 %	$ 2.91 M	USA
ADMA Biologics ADMA	147 M	$ 10.11	4.01 %	$ 2.41 B	USA
Adaptive Biotechnologies Corporation ADPT	-59.5 M	$ 29.84	5.26 %	$ 4.53 B	USA
Agenus AGEN	-3.08 M	$ 8.73	4.43 %	$ 260 M	USA
AIM ImmunoTech AIM	-14 M	$ 0.19	5.56 %	$ 308 K	USA
Akebia Therapeutics AKBA	-5.3 M	$ 0.91	5.26 %	$ 234 M	USA
Akari Therapeutics, Plc AKTX	-17.3 M	$ 8.76	0.46 %	$ 590 B	Britain
Aldeyra Therapeutics ALDX	-33.8 M	$ 0.92	4.88 %	$ 55.3 M	USA
Alector ALEC	-143 M	$ 1.99	9.94 %	$ 205 M	USA
Aligos Therapeutics ALGS	-24.2 M	$ 5.4	0.36 %	$ 53.4 M	USA
Alkermes plc ALKS	242 M	$ 42.76	2.42 %	$ 7.04 B	Irlanda
Allogene Therapeutics ALLO	-191 M	$ 1.5	0.33 %	$ 331 M	USA
Alnylam Pharmaceuticals ALNY	314 M	$ 219.89	0.08 %	$ 28.8 B	USA
Altimmune ALT	-88.1 M	$ 2.67	0.36 %	$ 235 M	USA
ALX Oncology Holdings ALXO	-102 M	$ 1.21	1.23 %	$ 64.9 M	USA